Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
OLE Period Key Inclusion Criteria:~* Successful completion of clinical study C601~* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)~OLE Period Key Exclusion Criteria:~* Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 90 days after study participation~* Any new disease, condition, or circumstance which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol (e.g., an anticipated change of care setting)~RW Period Key Inclusion Criteria:~* Provide voluntary, written informed consent (parent\[s\] / legal guardian\[s\] of participant); provide voluntary, written assent (participants, as appropriate); this includes consent for randomization and potential treatment with placebo for up to 16 weeks~* Currently participating in clinical study C602 and complete the OLE End of Treatment Visit procedures~RW Period Key Exclusion Criteria:~* Positive urine pregnancy test (in females of child-bearing potential)~* Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OLE DCCR (Type: EXPERIMENTAL): 75 - 525 mg DCCR
- RW DCCR (Type: EXPERIMENTAL): 75 - 525 mg DCCR
- RW Placebo (Type: PLACEBO_COMPARATOR): 75 - 525 mg Placebo for DCCR

Based on this trial design, predict the completion outcome and termination type (if applicable).